临床肿瘤学杂志
臨床腫瘤學雜誌
림상종류학잡지
CHINESE CLINICAL ONCOLOGY
2014年
12期
1081-1085
,共5页
强光亮%刘德若%中岛淳%安乐真树%似鸟纯一%牛久绫
彊光亮%劉德若%中島淳%安樂真樹%似鳥純一%牛久綾
강광량%류덕약%중도순%안악진수%사조순일%우구릉
趋化因子受体4%肺腺癌%组织芯片%预后
趨化因子受體4%肺腺癌%組織芯片%預後
추화인자수체4%폐선암%조직심편%예후
CC chemokine receptor 4( CCR4)%Lung adenocarcinoma%Tissue microarray%Prognosis
目的：探讨T1期肺腺癌肿瘤浸润淋巴细胞（ TILs）中趋化因子受体4（ CCR4）的表达及临床意义。方法采用组织芯片技术和免疫组织化学技术测定185例T1期肺腺癌TILs中CCR4的表达情况，分析CCR4表达与临床病理特征及预后的关系。结果 CCR4表达于TILs的胞浆，阳性表达率为（17?8±7?3）％，并以17?8％为界值分为低表达组和高表达组。CCR4阳性表达率与年龄、性别、吸烟史无关（ P＞0?05），与T分期、淋巴结转移、脉管浸润和复发有关（ P＜0?05）。 CCR4低表达组与高表达组患者的3年生存率分别为98?7％和88?1％，5年生存率分别为89?8％、88?1％，8年生存率分别为86?6％、51?6％，差异有统计学意义（ P＜0?05）；CCR4低表达组与高表达组患者的3年无复发生存率分别为93?3％、82?3％，5年无复发生存率分别为86?4％、74?5％，8年无复发生存率分别为83?4％、50?5％，差异有统计学意义（ P＜0?05）。结论 CCR4在T1期肺腺癌TILs中的高表达与肺腺癌侵袭性增强及淋巴结转移有关，有望成为预测肺腺癌预后和靶向治疗的指标。
目的：探討T1期肺腺癌腫瘤浸潤淋巴細胞（ TILs）中趨化因子受體4（ CCR4）的錶達及臨床意義。方法採用組織芯片技術和免疫組織化學技術測定185例T1期肺腺癌TILs中CCR4的錶達情況，分析CCR4錶達與臨床病理特徵及預後的關繫。結果 CCR4錶達于TILs的胞漿，暘性錶達率為（17?8±7?3）％，併以17?8％為界值分為低錶達組和高錶達組。CCR4暘性錶達率與年齡、性彆、吸煙史無關（ P＞0?05），與T分期、淋巴結轉移、脈管浸潤和複髮有關（ P＜0?05）。 CCR4低錶達組與高錶達組患者的3年生存率分彆為98?7％和88?1％，5年生存率分彆為89?8％、88?1％，8年生存率分彆為86?6％、51?6％，差異有統計學意義（ P＜0?05）；CCR4低錶達組與高錶達組患者的3年無複髮生存率分彆為93?3％、82?3％，5年無複髮生存率分彆為86?4％、74?5％，8年無複髮生存率分彆為83?4％、50?5％，差異有統計學意義（ P＜0?05）。結論 CCR4在T1期肺腺癌TILs中的高錶達與肺腺癌侵襲性增彊及淋巴結轉移有關，有望成為預測肺腺癌預後和靶嚮治療的指標。
목적：탐토T1기폐선암종류침윤림파세포（ TILs）중추화인자수체4（ CCR4）적표체급림상의의。방법채용조직심편기술화면역조직화학기술측정185례T1기폐선암TILs중CCR4적표체정황，분석CCR4표체여림상병리특정급예후적관계。결과 CCR4표체우TILs적포장，양성표체솔위（17?8±7?3）％，병이17?8％위계치분위저표체조화고표체조。CCR4양성표체솔여년령、성별、흡연사무관（ P＞0?05），여T분기、림파결전이、맥관침윤화복발유관（ P＜0?05）。 CCR4저표체조여고표체조환자적3년생존솔분별위98?7％화88?1％，5년생존솔분별위89?8％、88?1％，8년생존솔분별위86?6％、51?6％，차이유통계학의의（ P＜0?05）；CCR4저표체조여고표체조환자적3년무복발생존솔분별위93?3％、82?3％，5년무복발생존솔분별위86?4％、74?5％，8년무복발생존솔분별위83?4％、50?5％，차이유통계학의의（ P＜0?05）。결론 CCR4재T1기폐선암TILs중적고표체여폐선암침습성증강급림파결전이유관，유망성위예측폐선암예후화파향치료적지표。
Objective To investigate the expression of CC chemokine receptor 4( CCR4) in tumor infiltrating lymphocytes ( TILs) of T1 stage lung adenocarcinoma and analyze its correlation with clinicopathological characteristics and prognostic impact. Methods The expression of CCR4 in TILs was quantified by tissue microarray and immunohistochemistry in 185 T1 stage adenocarci?nomas. The relationship between the expression of CCR4 in TILs with clinicopathological characteristics and prognosis was analyzed. Results The expression of CCR4 was located in the nucleus of lymphocytes, with a positive expression ratio of(17?8±7?3)%. And patients were devided into high expression group and low expression group according 17?8%. The CCR4 expression was correlated with T stage, nodal involvement, lymphovascular invasion, and relapse( P<0?05) , but not with age, gender or smoking history( P>0?05) . The 5?year overall survival rate of CCR4 was 88?1%, lower than that of CCR4 low expression group( 89?8%) with statistically signifi?cant difference( P=0?038) . The 3?year overall survival rates of CCR4 high expression group and low expression group were 98?7% and 88?1%, the 5?year overall survival rates were 89?8% and 88?1%,and the 8?year overall survival rates were 86?6% and 51?6%,with statistical significance(P<0?05);The 3?year recurrence?free survival rates of CCR4 high expression group and low expression group were 93?3% and 82?3%, 3?year recurrence?free survival rates were 86?4% and 74?5%, and 8?year recurrence?free survival rates were 83?4% and 50?5% with statistical significance( P<0?05) . Conclusion The expression of CCR4 in TILs significantly increases with the aggression of lung adenocarcinoma and lymph node metastasis, indicating that it may be a predictor of prognosis and therapeutic tar?get in patients with lung adenocarcinoma.
